You are looking at 11 - 15 of 15 items

  • Author or Editor: Alan C. O’Connor x
Clear All Modify Search
You do not have access to this content

Michael P. Gallaher, Albert N. Link and Alan C. O’Connor

You do not have access to this content

Michael P. Gallaher, Albert N. Link and Alan C. O’Connor

This content is available to you

Michael P. Gallaher, Albert N. Link and Alan C. O’Connor

You do not have access to this content

Michael P. Gallaher, Albert N. Link and Alan C. O’Connor

Escalating energy demand may be the most important issue facing the United States and the world today. There is little disagreement that research and development (R & D) is needed to develop new energy technologies for the future; however, there is less agreement over the specific research agenda to be pursued and how that agenda is funded. This book addresses the social importance of new energy technologies, illustrates policy-relevant applications of evaluation techniques and proposes new perspectives for a US energy investment strategy.
You do not have access to this content

Alan C. O'Connor, Albert N. Link, Brandon M. Down and Laura M. Hillier

The Canada Foundation for Innovation (CFI) and the Canadian Institutes of Health Research (CIHR) allied to analyze the impact of their investments in medical imaging research. The CFI funds capital and operating programs for research infrastructure, and CIHR’s mandate concentrates its funding on research activity. It happens that CIHR funded research consumes CFI-funded infrastructure as an input in the innovation process. Apart from a few partnered programs, by design there is no coordination between CFI and CIHR funding decisions. Together, these agencies invested $916 million over a 14 year-period. In this paper, we evaluate the economic and health benefits from advancements in one funded area, namely computed tomography perfusion (CTP). CTP is an imaging technique that uses computed tomography to measure blood flow in organs and tissues. It is mostly used to assess acute ischemic stroke. The net social benefits attributable to these investments are substantially positive: the benefit-to-cost ratio is estimated to be between 6.66-to-1 and 9.99-to-1. We review how public investments from multiple funders comingle in the innovation process to deliver social value and improved health outcomes.